Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

from the Department of Defense to advance a next generation mammalian cell culture expression system for our recombinant chemical nerve agent bioscavenger program."

Conference Call and Webcast InformationPharmAthene management will be hosting a conference call to discuss the Company's third quarter 2011 financial and operating results.  The call is scheduled to begin at 8:30 a.m. Eastern Time on Wednesday, November 9, 2011 and is expected to last approximately 30 minutes. The dial-in number within the United States is 888-268-4176.  The dial-in number for international callers is 617-597-5493.  The participant passcode is 54772588.

A replay of the conference call will be available beginning at approximately 11:30 a.m. Eastern Time on November 9, 2011 until approximately 11:30 a.m. Eastern Time on December 9, 2011.  The dial-in number to access the replay from within the United States is 888-286-8010.   For international callers, the dial-in number is 617-801-6888.  The participant passcode is 88200860.

The conference call will also be webcast and can be accessed from the Company's website at www.PharmAthene.com.  A link to the webcast may be found under the Investor Relations section of the website.  

About PharmAthene, Inc.PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Recombinant BChE- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

  • In addition, pu
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    7. PharmAthene Completes $6.5 Million Registered Direct Offering
    8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
    11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/26/2015)... NORTH CHICAGO, Ill. , May 26, 2015 ... biopharmaceutical company, announced today that it has completed ... and commercial presence in oncology. Pharmacyclics is a ... (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ... "The companies, shared expertise, combined with AbbVie,s broad ...
    (Date:5/25/2015)... a science-driven healthcare company seeking to solve some of ... that Dame Marjorie Scardino , Chairman of the ... appointed to PureTech,s Board of Directors in the role ... Joi Ito , MIT Media Lab,s Director, has ... PureTech,s outgoing Chairman and co-founder, former Executive Vice President ...
    (Date:5/22/2015)... DUBLIN , May 22, 2015  Actavis plc ... of the U.S. Court of Appeals for the Second ... 2014 preliminary injunction requiring the Company to continue distribution ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   ... uphold this ruling, we intend to continue our strong ...
    (Date:5/22/2015)... -- Baylor Research Institute (BRI) at ... (TGen) in Phoenix, AZ , today ... and treatments for patients with a broad range of cancers. ... new clinical trials and access to technology to drive the ... to bedside across Baylor Scott & White Health,s ...
    Breaking Biology Technology:AbbVie Completes Acquisition of Pharmacyclics 2AbbVie Completes Acquisition of Pharmacyclics 3AbbVie Completes Acquisition of Pharmacyclics 4AbbVie Completes Acquisition of Pharmacyclics 5AbbVie Completes Acquisition of Pharmacyclics 6PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4
    ... Jeff Cunningham and Lynn Jordan , ... Massachusetts, USA , Introduction ... is an optional accessory to the Sciclone Advanced Liquid Handler (ALH). This ... wells or columns of 96 and 384 well microplates for purposes of ...
    ... Geoffrey Grove, Ed Alderman Applied Science and ... Monica Adams, Jason Brennan Development Integration, ... Overview , ... Kit is designed to eliminate the requirement for extended bacterial growth ...
    ... Rudy Willebrords 1 and Bart Moyson 2 , ... & Development, a division of Janssen Pharmaceutica N.V., Laboratory of Virology, Beerse, Belgium ... Caliper Life Sciences Benelux NV, Teralfene, Belgium , ... purpose of this paper is to report the performance obtained by dispensing 1μL ...
    Cached Biology Technology:Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 2Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 3Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 4Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 2Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 3Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 4Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 696 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 296 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 3
    (Date:5/25/2015)... 2015  Australia,s market for wearable technologies is considered ... the advent of several trials and prototypes. The release ... expected to ignite interest in wearables as well as ... . This in turn will spur greater innovation ... partnerships amongst vendors and distributors. Photo ...
    (Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
    (Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
    Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3
    ... , , , , , ... AUDIO: Plants capable of producing oils for industrial chemicals and human health are ... Click here for more information. , , , ... , , , , , ...
    ... de-acetylase (HDAC) inhibitor panobinostat is able to target and ... published in BioMed Central,s open access journal Breast ... Center have shown that panobinostat was able to destroy ... Approximately 15% of breast cancers are found at ...
    ... Barcelona, 20 May 2012. The Stem Cells and Cancer ... the Vall d,Hebrn Institute of Oncology (VHIO) has identified ... drugs used in clinical trials for colon cancer treatment. ... collaboration with Professor Alberto Muozs laboratory at the Instituto ...
    Cached Biology News:Supercharged safflower 2Supercharged safflower 3Supercharged safflower 4Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3
    ... Large T antigen initiates replication ... replication in the presence of ... product can be used in ... Replication Kit cat. no. 8050. ...
    NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
    Request Info...
    ...
    Biology Products: